Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better

Documenti analoghi

• Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better
  di: Franchini, Massimo
  Pubblicazione: (2010)
• The increased demand for plasma-derived factor VIII in Italy
  di: Arcieri, Romano, et al.
  Pubblicazione: (2017)
• High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis
  di: Messori, Andrea, et al.
  Pubblicazione: (2018)
• Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies
  di: Mannucci, Pier Mannuccio, et al.
  Pubblicazione: (2017)
• Further comments on “High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis”
  di: Messori, Andrea, et al.
  Pubblicazione: (2019)